Plateletcrit as a prognostic marker in Hodgkin lymphoma: A pilot study

Plateletcrit for Hodgkin lymphoma



plateletcrit, Hodgkin lymphoma, prognosis


Background/Aim: Hodgkin lymphoma (HL) is a lymphoproliferative malignancy associated with inflammation. Plateletcrit (PCT) is a mean platelet volume (MPV) and platelet count-derived marker that is useful for evaluating malignancies and inflammatory diseases. International Prognostic Score (IPS-7) and more recently, IPS-3, are two indices indicating the prognosis of patients; however, widespread and easy to interpret prognostic markers are still needed for HL evaluation. Very few studies evaluating the prognostic significance of platelet indices in HL have been published, so we aimed to show the relationship between PCT and other adverse prognostic factors in HL and evaluate whether PCT can be used as a prognostic marker in HL.

Methods: After excluding patients with insufficient data, 75 patients diagnosed with HL and 150 healthy controls were retrospectively analyzed in this case-control study. Evaluation of relationship of PCT and adverse HL prognostic factors, such as age, gender, hemoglobin, leukocytes, lymphocytes (absolute value and percentage), albumin, Ann Arbor stage and B symptoms, IPS-3 and-7 prognostic scores and post-treatment relapse, and progression-free survival of the patients were studied.

Results: Mean MPV values were significantly lower, mean platelet values were significantly higher inpatient group (all P<0.001). Patients with high sedimentation had significantly higher mean PCT than those without (P=0.031) and a moderately positive correlation between PCT and sedimentation were found (r=0.33, P<0.01). Mean PCT values after treatment significantly decreased compared to baseline levels (P<0.001).

Conclusion: PCT may be useful as a prognostic marker in HL. Further studies were needed to evaluate the relationship between PCT and other prognostic factors, such as IPS-3 and -7.


Download data is not yet available.

Author Biographies

Emine Guchan Alanoglu, Suleyman Demirel University School of Medicine, Department of Hematology, Isparta, Turkey

Asisstant Prof. Dr. of Hematology Department

Kamuran Yuceer, Suleyman Demirel University School of Medicine, Department of Internal Medicine, Isparta, Turkey

Assitant Dr. of Internal medicine

Hande Nur Eroglu, Suleyman Demirel University School of Medicine, Department of Public Health, Isparta, Turkey

Specialist of Public Health


Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998 Apr;162:261-80. doi: 10.1111/j.1600-065x.1998.tb01447. x. PMID: 9602370. DOI:

Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991 Feb 9;337(8737):320-2. doi: 10.1016/0140-6736(91)90943-j. PMID: 1671232. DOI:

Momotow J, Borchmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J Clin Med. 2021 Mar 8;10(5):1125. doi: 10.3390/jcm10051125. PMID: 33800409; PMCID: PMC7962816. DOI:

Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245. Epub 2012 Oct 1. PMID: 23023715; PMCID: PMC3534167. DOI:

von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12. PMID: 27496309; PMCID: PMC5637390. DOI:

Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015 Sep;125(9):3384-91. doi: 10.1172/JCI80011. Epub 2015 Sep 1. PMID: 26325035; PMCID: PMC4588282. DOI:

Moy RH, Younes A. Immune Checkpoint Inhibition in Hodgkin Lymphoma. Hemasphere. 2018 Feb 16;2(1):e20. doi: 10.1097/HS9.0000000000000020. PMID: 31723749; PMCID: PMC6745954. DOI:

Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015 Jul 30;126(5):582-8. doi: 10.1182/blood-2014-08-531582. Epub 2015 Jun 24. PMID: 26109205; PMCID: PMC4520875. DOI:

Ustaoglu G, Erdal E, Inanır M. Does periodontitis affect mean platelet volume (MPV) and plateletcrit (PCT) levels in healthy adults? Rev Assoc Med Bras (1992). 2020 May 15;66(2):133-8. doi: 10.1590/1806-9282.66.2.133. PMID: 32428146. DOI:

Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer. 2020 Feb 25;11(10):2800-7. doi: 10.7150/jca.41122. PMID: 32226498; PMCID: PMC7086273. DOI:

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7. PMID: 26343802; PMCID: PMC4881845. DOI:

Karagoz B, Sucullu I, Sayan O, Bilgi O, Tuncel T, Filiz A, et al. Platelet indices in patients with colorectal cancer. Open Medicine. 2010;5(3): 365-8. doi: 10.2478/s11536-009-0077-7 DOI:

Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019 Apr 17; 2019:9213074. doi: 10.1155/2019/9213074. PMID: 31148950; PMCID: PMC6501263. DOI:

Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, et al. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol. 2015 Jan;3(1):197-201. doi: 10.3892/mco.2014.436. Epub 2014 Oct 6. PMID: 25469294; PMCID: PMC4251106. DOI:

Shen WJ, Fu S, Li N, Li LL, Cao ZG, Li C, et al. Decreased Mean Platelet Volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1769-72. doi: 10.22034/APJCP.2017.18.7.1769. PMID: 28749103; PMCID: PMC5648377.

Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget. 2018 Apr 20;9(30):21190-200. doi: 10.18632/oncotarget.25002. PMID: 29765530; PMCID: PMC5940371. DOI:

Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. Cancers (Basel). 2018 Nov 14;10(11):441. doi: 10.3390/cancers10110441. PMID: 30441823; PMCID: PMC6266827. DOI:

Randi ML, Rossi C, Barbone E, Pietrogrande F, Girolami A. Incidence of thrombocytosis in lymphomas. Leuk Lymphoma. 1992 May;7(1-2):139-41. doi: 10.3109/10428199209053614. PMID: 1472925. DOI:

Zhu X, Cao Y, Lu P, Kang Y, Lin Z, Hao T, et al. Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer. Sci Rep. 2018 Aug 7;8(1):11814. doi: 10.1038/s41598-018-29293-x. PMID: 30087357; PMCID: PMC6081379. DOI:

Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005 Aug 1;23(22):5052-60. doi: 10.1200/JCO.2005.11.080. Epub 2005 Jun 13. PMID: 15955904. DOI:

Tao Y, He X, Qin Y, Liu P, Zhou S, Yang J, et al. Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015. Epub ahead of print. PMID: 34296652. DOI:

Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early-stage classical Hodgkin lymphoma. Br J Haematol. 2018 Feb;180(4):545-9. doi: 10.1111/bjh.15054. Epub 2017 Dec 21. PMID: 29271057. DOI:






Research Article

How to Cite

Ozbalci D, Alanoglu EG, Yuceer K, Eroglu HN. Plateletcrit as a prognostic marker in Hodgkin lymphoma: A pilot study: Plateletcrit for Hodgkin lymphoma. J Surg Med [Internet]. 2023 Jan. 24 [cited 2024 May 26];7(1):91-4. Available from: